Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses

Journal of Immunology

Volumn 184, Issue 11, 2010, Pages 6514-6521

  Abdul Alim, C Siddiq ^a   Li, Yongqing ^a   Yee, Cassian ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERED PEPTIDE LIGAND; EPITOPE; HLA ANTIGEN CLASS 1; LIGAND; MELAN A; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG; MART1 ANTIGEN; TUMOR ANTIGEN; TUMOR PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; CLONE; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; GENETIC SCREENING; GENETICS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOUSE; MUTAGENESIS; MUTANT; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; TUMOR; WILD TYPE; GENETIC PROCEDURES; IMMUNOLOGY; MELANOMA; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; GENETIC TECHNIQUES; HUMANS; MELANOMA; NEOPLASM PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 77953441872     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0900448     Document Type: Article

References (28)

1. Zaremba, S., E. Barzaga, M. Zhu, N. Soares, K. Y. Tsang, and J. Schlom. 1997. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 57: 4570-4577. (Pubitemid 27441063)
2. Boon, T., and P. van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183: 725-729.
3. Knuth, A., T. Wölfel, E. Klehmann, T. Boon, and K. H. Meyer zum Büschenfelde. 1989. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc. Natl. Acad. Sci. USA 86: 2804-2808.
4. Espinoza-Delgado, I. 2002. Cancer vaccines. Oncologist 7(Suppl 3): 20-33.
5. Overwijk, W. W., and N. P. Restifo. 2001. Creating therapeutic cancer vaccines: notes from the battlefield. Trends Immunol. 22: 5-7.
6. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137-148.
7. + T cell repertoires primed with agonist and native peptides derived from a tumor-associated antigen. J. Immunol. 180: 1526-1534.
8. Kazansky, D. B. 2007. Intrathymic selection: new insight into tumor immunology. Adv. Exp. Med. Biol. 601: 133-144.
9. McMahan, R. H., and J. E. Slansky. 2007. Mobilizing the low-avidity T cell repertoire to kill tumors. Semin. Cancer Biol. 17: 317-329.
10. Morgan, D. J., H. T. Kreuwel, S. Fleck, H. I. Levitsky, D. M. Pardoll, and L. A. Sherman. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160: 643-651.
11. Ohashi, P. S., S. Oehen, K. Buerki, H. Pircher, C. T. Ohashi, B. Odermatt, B. Malissen, R. M. Zinkernagel, and H. Hengartner. 1991. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65: 305-317.
12. Zehn, D., and M. J. Bevan. 2006. T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity 25: 261-270.
13. Chen, J. L., P. R. Dunbar, U. Gileadi, E. Jäger, S. Gnjatic, Y. Nagata, E. Stockert, D. L. Panicali, Y. T. Chen, A. Knuth, et al. 2000. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J. Immunol. 165: 948-955.
14. Valmori, D., J. F. Fonteneau, C. M. Lizana, N. Gervois, D. Liénard, D. Rimoldi, V. Jongeneel, F. Jotereau, J. C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160: 1750-1758. (Pubitemid 28110836)
15. Fong, L., Y. Hou, A. Rivas, C. Benike, A. Yuen, G. A. Fisher, M. M. Davis, and E. G. Engleman. 2001. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 98: 8809-8814.
16. Rivoltini, L., Y. Kawakami, K. Sakaguchi, S. Southwood, A. Sette, P. F. Robbins, F. M. Marincola, M. L. Salgaller, J. R. Yannelli, E. Appella, et al. 1995. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154: 2257-2265.
17. Singh, R. A., Y. C. Zang, A. Shrivastava, J. Hong, G. T. Wang, S. Li, M. V. Tejada-Simon, M. Kozovska, V. M. Rivera, and J. Z. Zhang. 1999. Th1 and Th2 deviation of myelin-autoreactive T cells by altered peptide ligands is associated with reciprocal regulation of Lck, Fyn, and ZAP-70. J. Immunol. 163: 6393-6402.
18. Valmori, D., N. Gervois, D. Rimoldi, J. F. Fonteneau, A. Bonelo, D. Liénard, L. Rivoltini, F. Jotereau, J. C. Cerottini, and P. Romero. 1998. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide. J. Immunol. 161: 6956-6962. (Pubitemid 28562243)
19. McCue, D., K. R. Ryan, D. C. Wraith, and S. M. Anderton. 2004. Activation thresholds determine susceptibility to peptide-induced tolerance in a heterogeneous myelin-reactive T cell repertoire. J. Neuroimmunol. 156: 96-106.
20. Li, Y., M. Bleakley, and C. Yee. 2005. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J. Immunol. 175: 2261-2269. (Pubitemid 41113833)
21. Speiser, D. E., P. Baumgaertner, V. Voelter, E. Devevre, C. Barbey, N. Rufer, and P. Romero. 2008. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc. Natl. Acad. Sci. USA 10504: 3849-3854.
22. Borbulevych, O. Y., F. K. Insaidoo, T. K. Baxter, D. J. Powell, Jr., L. A. Johnson, N. P. Restifo, and B. M. Baker. 2007. Structures of MART-126/27-35 peptide/ HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition. J. Mol. Biol. 372: 1123-1136.
23. Ding, Y. H., B. M. Baker, D. N. Garboczi, W. E. Biddison, and D. C. Wiley. 1999. Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical. Immunity 11: 45-56.
24. Kersh, G. J., M. J. Miley, C. A. Nelson, A. Grakoui, S. Horvath, D. L. Donermeyer, J. Kappler, P. M. Allen, and D. H. Fremont. 2001. Structural and functional consequences of altering a peptide MHC anchor residue. J. Immunol. 166: 3345-3354.
25. Nino-Vasquez, J. J., G. Allicotti, E. Borras, D. B. Wilson, D. Valmori, R. Simon, R. Martin, and C. Pinilla. 2004. A powerful combination: the use of positional scanning libraries and biometrical analysis to identify cross-reactive T cell epitopes. Mol. Immunol. 40: 1063-1074.
26. + cytolytic T-lymphocyte clone. Cancer Res. 62: 2058-2063.
27. + T cell clone. Eur. J. Immunol. 36: 27-36.
28. Sliz, P., O. Michielin, J. C. Cerottini, I. Luescher, P. Romero, M. Karplus, and D. C. Wiley. 2001. Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes. J. 2Immunol. 167: 3276-3284.